VolitionRx Reports 112% Revenue Growth Amid Expansion in Diagnostics

The company’s growth follows clinical validation for its Nu.Q NETs assay, which recently received peer-reviewed recognition for predicting mortality and renal replacement needs in sepsis patients. A government-backed $7.3 million program in France is set to begin recruitment this September to further assess the diagnostic’s real-world utility. Beyond sepsis, VolitionRx is expanding into trauma care and chronic disease management, citing a $1 billion addressable market for NETosis-related conditions.

Technological progress remains a primary focus, with the company developing a finger-prick lateral flow assay designed for point-of-care environments. Simultaneously, VolitionRx is advancing its Capture-Seq platform, which recently demonstrated over 95% sensitivity for early-stage cancers. In the veterinary sector, the submission of a clinical manuscript regarding feline lymphoma testing is expected to trigger a $5 million milestone payment, complementing the existing availability of its canine diagnostics in over 20 countries. As the firm refines its commercial strategy, it continues to transition from internal development toward high-volume licensing agreements with global diagnostic partners.